Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.38 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | UGT1A4 | P22310 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17157402 | 0.85 | ESR1 (0.36) | SCN10ACYP19A1UGT1A4PDE4D | |
| SCHEMBL27755359 | 0.83 | SCN10A (0.35) | SCN10ACYP19A1UGT1A4PDE4D | |
| SCHEMBL29552245 | 0.79 | PIEZO1 (0.41) | CSNK2A1 | |
| SCHEMBL7886912 | 0.79 | PIEZO1 (0.41) | CSNK2A1 | |
| SCHEMBL195478 | 0.77 | CHRNA1 (0.38) | SCN10ACYP19A1UGT1A4PDE4D | |
| SCHEMBL30133886 | 0.74 | SCN10A (0.34) | SCN10A | |
| SCHEMBL17157437 | 0.74 | AR (0.38) | CSNK2A1SCN10ACYP19A1 | |
| SCHEMBL17157434 | 0.74 | SCN10A (0.34) | SCN10A | |
| SCHEMBL17157388 | 0.74 | AR (0.35) | SCN10A | |
| SCHEMBL2794148 | 0.73 | CSNK2A1 (0.40) | CSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8754100-B2 | Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-06-17 | — | — | US | disclosed |
| EP-2615090-A1 | Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors | Eisai R&D Management Co., Ltd. (JP) | 2013-07-17 | — | — | EP | disclosed |
| EP-2401276-B1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS BETA AMYLOID PRODUCTION INHIBITORS | EISAI R&D MAN CO LTD (JP) | 2013-06-05 | — | — | EP | disclosed |
| US-20120053171-A1 | Nitrogen-Containing Fused Heterocyclic Compounds and Their use as Beta Amyloid Production Inhibitors | EISAI R&D MANAGEMENT CO., LTD., (JP) | 2012-03-01 | — | — | US | disclosed |
| CN-102333777-A | Nitrogen-containing fused heterocyclic compounds and their use as beta-amyloid production inhibitors | EISAI R&D MAN CO LTD | 2012-01-25 | — | — | CN | disclosed |
| EP-2401276-A1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS BETA AMYLOID PRODUCTION INHIBITORS | Eisai R&D Management Co., Ltd. (JP) | 2012-01-04 | — | — | EP | disclosed |
| WO-2010098487-A1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS BETA AMYLOID PRODUCTION INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053171-A1 | Nitrogen-Containing Fused Heterocyclic Compounds and Their use as Beta Amyloid Production Inhibitors | BACE1, APP, PSEN1 | CSNK2A1 1593/4885SCN10A 74/4885CYP19A1 1836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.